SEC Filing Summary: AspenBio Pharma, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AspenBio Pharma, Inc. on June 25, 2012. The filing addresses the Company's compliance with Nasdaq listing standards following a notification of non-compliance regarding minimum stockholders' equity requirements.
Key Financial Metrics and Capital Raise
- Capital Raised: The Company consummated a firm commitment public offering of 6,100,000 shares of Common Stock.
- Offering Price: $2.00 per share.
- Net Proceeds: Approximately $10.8 million after underwriting discounts, commissions, and estimated offering expenses.
- Warrants Issued: Underwriters received warrants to purchase 305,000 shares at an exercise price of $2.50 per share, exercisable from June 19, 2013, to June 19, 2017.
- Over-Allotment Option: Underwriters hold a 45-day option to purchase up to 915,000 additional shares at $2.00 per share.
- Other Metrics: The filing does not provide specific data on revenue, profit, operating cash flow, margins, or existing debt levels.
Material Changes and Listing Status
On May 15, 2012, the Company received notice from Nasdaq regarding failure to comply with Rule 5550(b)(1), which requires a minimum of $2,500,000 in stockholders' equity. The June 25, 2012 offering was executed specifically to address this deficiency. As of the closing of the offering, the Company believes it has regained compliance with the stockholders' equity requirement.
Outlook, Risks, and Contingencies
- Delisting Risk: Nasdaq will continue to monitor compliance. If the Company is not in compliance with Rule 5550(b)(1) at the time of filing its Form 10-Q for the quarter ended June 30, 2012, it may be subject to delisting from the Nasdaq Capital Market.
- Management Commentary: The filing confirms the closing of the offering and the issuance of the press release (Exhibit 99.1) but contains no forward-looking guidance on product development or future financial performance.
Key Facts for Investor Verification
- Verify the Company's stockholders' equity balance in the upcoming Form 10-Q for the quarter ended June 30, 2012, to confirm sustained Nasdaq compliance.
- Monitor the exercise of the underwriters' over-allotment option within the 45-day window following June 25, 2012.
- Review the attached press release (Exhibit 99.1) for additional details on the use of proceeds.
- Note that the filing text does not provide clear values for revenue, net income, or cash flow from operations.